pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumor, glioblastoma, colorectal cancer, melanoma
Conditions
Interventions
Gold Standard:Pathological Diagnosis
Index test:LRRC15 targeted SPECT/CT
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.(1) The subject or his legal representative can sign the signature and date of the informed consent; 2.(2) Commitment to abide by the research procedures and cooperate with the implementation of the whole process of research; 3.(3) Adult subjects (aged 18 or above), male or female; 4.(4) Patients with clinically suspected or diagnosed malignant tumors such as pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumor, glioblastoma, colorectal cancer, melanoma, etc. (supporting evidence includes serum-related tumor markers, ultrasound, CT, MRI and other imaging materials and histopathological examination, etc.), and they are generally in good condition; 5.(5) Women in reproductive period should use contraception for at least one month before screening, and promise to use contraception during the whole study period and continue until the specified time after the end of the study; 6.(6) Other set selection criteria. Each subject must meet all the selection criteria to be eligible to participate in the study. Healthy subjects (1) Any serious or unstable medical condition; Those who have acute illness before the study; Past or existing malignancy Tumor; (2) pregnant and lactating women; (3) Surgery within 6 months prior to the trial, which is judged by the investigator to affect absorption, distribution, metabolism, and excretion He who; (4) Those who have used any drugs (including prescription drugs, over-the-counter drugs, and Chinese herbal medicines) within 2 weeks before the trial; (5) Participated in other research studies involving radioactive material (within the past 12 months); (6) any other factors affecting the results of the study.
Exclusion criteria
Exclusion criteria: 1.(1) Unable to complete SPECT/CT or PET/CT examination (including recumbent, claustrophobia, radiation phobia, etc.); 2.(2) Patients who are known to be allergic to LRRC15 specific radioactive molecular imaging agents or synthetic excipients; The fasting blood glucose level before injection of [18F]FDG exceeded 11.0 mmol/L; 3.(3) Patients during pregnancy or lactation; 4.(4) There are other factors that are not suitable to participate in this test.All baseline subjects who meet any exclusion criteria will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Standardized uptake values assessment of region of interest;Accuracy;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Radioactivity in the blood and urine samples;Pathological sections of tumour tissue;Blood test, urine test,liver and kidney function and other biochemical indicators;electrocardiography,ECG; | — |
Countries
China
Contacts
Public ContactXiaoli Lan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed